As Revlim­id faces more com­pe­ti­tion, Bris­tol My­er­s' goal is to 'grow the com­pa­ny'

Bris­tol My­ers Squibb’s Q3 num­bers were down on the lat­est quar­ter, but the Big Phar­ma is look­ing to stay the course, main­tain­ing over­all 2022 rev­enue guid­ance in light of gener­ics eat­ing away at the prof­its of megablock­buster Revlim­id.

CEO Gio­van­ni Caforio told in­vestors and an­a­lysts on the Q3 earn­ings call Wednes­day morn­ing that the phar­ma’s pri­or­i­ties are still the same: keep­ing up with the ap­proved prod­ucts, ex­pand­ing to new in­di­ca­tions and mov­ing the pipeline for­ward. In that same vein, Caforio is look­ing to “pri­or­i­tize busi­ness de­vel­op­ment op­por­tu­ni­ties” with­out ex­act­ly elab­o­rat­ing. Deal­mak­ing had been some­thing that the CEO hint­ed at on Bris­tol My­ers’ pre­vi­ous earn­ings call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER